CD152 (CTLA-4) regulates effector functions of CD8+ T lymphocytes by repressing Eomesodermin
- PMID: 19224637
- DOI: 10.1002/eji.200838770
CD152 (CTLA-4) regulates effector functions of CD8+ T lymphocytes by repressing Eomesodermin
Abstract
CD8(+) T lymphocytes are required for effective host defense against pathogens and also for mediating effector responses against uncontrolled proliferating self-tissues. In this study, we determine that individual CD8(+) T cells are tightly controlled in their effector functions by CD152 (CTLA-4). We demonstrate that signals induced by CD152 reduce the frequency of IFN-gamma and granzyme B expressing CD8(+) T cells independently of the transcription factors T-bet or cKrox by selectively inhibiting accumulation of Eomesodermin mRNA and protein. Ectopic expression of Eomesodermin reversed the CD152-mediated inhibition of effector molecule production. Additionally, enhanced cytotoxicity of individual CD8(+) T cells differentiated in the absence of CD152 signaling was determined in vivo. These novel insights extend our understanding of how immune responses of CD8(+) T cells are selectively modulated.
Similar articles
-
Control of effector CD8+ T cell function by the transcription factor Eomesodermin.Science. 2003 Nov 7;302(5647):1041-3. doi: 10.1126/science.1090148. Science. 2003. PMID: 14605368
-
A Th17-like developmental process leads to CD8(+) Tc17 cells with reduced cytotoxic activity.Eur J Immunol. 2009 Jul;39(7):1716-25. doi: 10.1002/eji.200939412. Eur J Immunol. 2009. PMID: 19544308
-
Differential transcription of Eomes and T-bet during maturation of mouse uterine natural killer cells.J Leukoc Biol. 2005 Dec;78(6):1347-55. doi: 10.1189/jlb.0305142. Epub 2005 Oct 4. J Leukoc Biol. 2005. PMID: 16204645
-
Signalling through TEC kinases regulates conventional versus innate CD8(+) T-cell development.Nat Rev Immunol. 2007 Jun;7(6):479-85. doi: 10.1038/nri2091. Nat Rev Immunol. 2007. PMID: 17479128 Review.
-
Pathways of memory CD8+ T-cell development.Eur J Immunol. 2009 Aug;39(8):2083-7. doi: 10.1002/eji.200939555. Eur J Immunol. 2009. PMID: 19637204 Review.
Cited by
-
Blocking TGF-β Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor.Onco Targets Ther. 2019 Nov 11;12:9527-9538. doi: 10.2147/OTT.S224013. eCollection 2019. Onco Targets Ther. 2019. PMID: 31807028 Free PMC article. Review.
-
Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects.J Clin Invest. 2012 Oct;122(10):3718-30. doi: 10.1172/JCI61931. Epub 2012 Sep 4. J Clin Invest. 2012. PMID: 22945631 Free PMC article.
-
EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4+ T cells in chronic lymphocytic leukemia.Leukemia. 2021 Aug;35(8):2311-2324. doi: 10.1038/s41375-021-01136-1. Epub 2021 Feb 1. Leukemia. 2021. PMID: 33526861 Free PMC article.
-
Ipilimumab reshapes T cell memory subsets in melanoma patients with clinical response.Oncoimmunology. 2016 Feb 18;5(7):1136045. doi: 10.1080/2162402X.2015.1136045. eCollection 2016 Jul. Oncoimmunology. 2016. PMID: 27622012 Free PMC article.
-
Betting on immunotherapy for melanoma.Curr Oncol Rep. 2009 Sep;11(5):397-404. doi: 10.1007/s11912-009-0053-z. Curr Oncol Rep. 2009. PMID: 19679015 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials